摘要
目的:分析医院肿瘤病区住院患者静脉用质子泵抑制剂(proton pump inhibitors,PPIs)使用情况及其合理性,为临床合理用药提供参考。方法:从医院信息系统中调取2020年11月—12月肿瘤病区静脉用PPIs患者210例病历资料,依据相关法规,统计与分析静脉用PPIs的使用情况及其合理性。结果:患者PPIs的使用目的以恶性肿瘤术后化疗为主(占27.62%),抗肿瘤药物和血液系统用药分别占62.08%、10.77%;在静脉用PPIs中,兰索拉唑的使用频次占46.69%,使用单个品种的病例数占78.10%,均次疗程为(4.35±4.41)d,疗程小于或等于2 d的占40.48%;不合理用药类型中以超疗程用药(占31.34%)、超剂量(占22.39%)和选药欠合理(占14.93%)为主;PPIs与二氢吡啶类钙离子拮抗剂、卡培他滨片和抗菌药物等联用存在潜在药物相互作用。结论:医院肿瘤病区用药结构与疾病治疗基本相符,静脉用PPIs使用情况基本合理,但仍存在部分不合理使用现象;医院行政部门应不断完善管理制度,规范用药,以确保临床用药的合理性、安全性。
Objective:To analyze the usage and rationality of intravenous proton pump inhibitors(PPIs)for inpatients in the tumor ward of a hospital so as to provide reference for rational drug use in clinic.Methods:The medical records of 210 patients with intravenous PPIs in tumor ward from November to December 2020 were collected from hospital information System.According to the relevant laws and regulations,the usage of intravenous PPIs and its rationality were analyzed statistically.Results:Among the 210 patients,the main purpose of use was postoperative chemotherapy for malignant tumors(27.62%),and 62.08% and 10.77% were treated with antitumor drugs and hematological drugs,respectively.In intravenous PPIs,the use frequency of lansoprazole accounted for 46.69%,the number of cases using a single variety accounted for 78.10%,the average course of treatment was(4.35±4.41)d,the course of treatment was less than or equal to 2 d accounted for 40.48%;The main types of irrational drug use were over-course of drug use(31.34%),over-dose(22.39%)and irrational drug selection(14.93%).PPIs have potential drug interactions with dihydropyridine calcium antagonists,capecitabine tablets and antibacterials.Conclusion:The structure of drug use in the tumor ward of the hospital is basically consistent with the treatment of disease,and the use of intravenous PPIs is acceptable overall,but some unreasonable uses still exist.The administrative department of a hospital should constantly improve the management system and standardize drug use in order to ensure the rationality and safety of clinical drug use.
作者
邹音
张桂芬
张敏
ZOU Yin;ZHANG Gui-fen;ZHANG Min(Department of Pharmacy,Changshu No.1 People's Hospital,Changshu Jiangsu 215500,China;Department of Pharmacy,Changshu Hospital Affiliated to Soochow University,Changshu Jiangsu 215500,China)
出处
《抗感染药学》
2022年第1期30-35,共6页
Anti-infection Pharmacy
